March 2, 2021
Kissei Pharmaceutical said on March 1 that it has filed a new drug application in Japan for its complement C5a receptor (C5aR) inhibitor avacopan for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis. Avacopan could potentially become the first-in-class...read more